Phase 1b/2 trial of AsiDNA™ in combination with olaparib in the United States in recurrent ovarian, breast and metastatic castration-resistant prostate cancer continues to enroll. | April 24, 2023
> Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally> Cash position of €26.9 million as of June 30, 2022> Financial visibility assured until Q2 2023PARIS (BUSINESS WIRE) Regulatory News:Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen1: ONXEO), hereafte.
Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
> Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally > Cash position of €26.9 million as of June 30, 2022 > Financial visibility assured until Q2 2023 Regulatory
Biotechnology Firm Onxeo Appoints Dr. Shefali Agarwal as President and CEO indianewengland.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indianewengland.com Daily Mail and Mail on Sunday newspapers.